Mounjaro Cost in the UK: Prices, Eligibility and NHS Access in 2026

Mounjaro has become one of the most discussed prescription treatments for weight management in the UK. The headline price, however, tells only part of the story. The amount a patient pays can vary by dose and provider, while access through the NHS depends on clinical need and a phased rollout—not simply whether someone meets the medicine’s general licence.

Mounjaro is the brand name for tirzepatide. It is a prescription-only medicine and should be supplied after an appropriate clinical assessment. It is not suitable for cosmetic or rapid weight loss in people who do not meet the medical criteria.

This guide explains typical private costs, the difference between licensed eligibility and NHS access, what treatment usually involves and what to check before choosing a provider.

How Much Does Mounjaro Cost Privately in the UK?

A Mounjaro KwikPen contains four once-weekly doses, normally covering four weeks of treatment. Private patients pay for the medicine and may also pay for assessment, dispensing, delivery and follow-up support.

As of mid-2026, advertised private prices commonly range from roughly £130 to more than £350 for a four-week supply, depending on dose and provider. Promotional starter prices can fall outside the typical range, so the renewal price matters more than the first order.

The table below provides a broad market guide rather than a quotation:

Weekly dose	Broad private price range for four weeks
2.5 mg	Approximately £130–£210
5 mg	Approximately £150–£235
7.5 mg	Approximately £200–£300
10 mg	Approximately £230–£330
12.5 mg	Approximately £260–£360
15 mg	Approximately £280–£375

These ranges are based on advertised UK provider prices observed in 2026 and may change. Discounts, subscriptions and manufacturer arrangements can affect the final amount. NICE lists the medicine’s prices before VAT and private service charges at £133 for 2.5 mg, £180 for 5 mg, £255 for 7.5 mg or 10 mg, and £330 for 12.5 mg or 15 mg. Retail pharmacies may charge above or below those figures because their acquisition costs and service models differ.

Do not assume that treatment will automatically progress to the highest dose. The appropriate dose depends on response, tolerability and the prescriber’s judgement. Paying less for a higher-dose pen is not a reason to alter the prescribed schedule or extract unofficial “extra” doses.

Why Private Prices Differ

Dose strength

Higher-dose pens generally cost more. This means the monthly cost can rise if a prescriber recommends dose escalation.

What the service includes

Some providers bundle the medicine with clinical review, needles, swabs, a sharps bin, tracked cold-chain delivery and follow-up support. Others advertise a lower medicine price and add delivery or consultation charges later.

Introductory discounts

A low first-month price may apply only to new customers or the 2.5 mg starting dose. Compare the likely cost of several months rather than choosing on the basis of a voucher.

Provider and supply arrangements

Private pharmacies negotiate their own purchasing and rebate arrangements. Mounjaro’s UK list prices increased in September 2025, contributing to wider differences between providers and dose levels.

Ongoing clinical support

A service that reviews side effects, nutrition, weight trajectory and suitability may cost more than a basic dispensing model. More expensive does not automatically mean better, but a provider should offer meaningful access to a qualified clinician.

A Better Way to Compare the Cost

Before paying, request the complete price for the prescribed dose and ask:

Does the advertised amount include the clinical assessment and prescription?
Are delivery, needles and a sharps bin included?
Does the price change at 5 mg, 7.5 mg and higher doses?
Is a subscription required, and how can it be cancelled?
Are follow-up reviews included?
Is there a charge if the clinician decides treatment is unsuitable?
What happens if the product is unavailable or delayed?
How are refunds and damaged cold-chain deliveries handled?

A provider that gives clear answers before payment is preferable to one that relies on a striking starter price and reveals the remaining costs at checkout.

Can You Get Mounjaro Through the NHS?

Yes, tirzepatide is recommended by NICE as an NHS option for weight management, but access is being introduced in stages. The criteria for NHS treatment are narrower than the medicine’s general UK marketing authorisation, and meeting the headline NICE criteria does not guarantee immediate access in every area.

NICE recommends tirzepatide alongside a reduced-calorie diet and increased physical activity for adults who initially have:

a BMI of at least 35 kg/m²; and
at least one weight-related comorbidity.

Relevant conditions include hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, prediabetes and type 2 diabetes. NICE normally reduces the BMI threshold by 2.5 kg/m² for people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean backgrounds because health risks can occur at a lower BMI.

Why access remains limited

NHS England is prioritising people with the greatest clinical need during the initial rollout. NICE’s public information indicates that access is expanding in stages over the first three years. Around June 2026, the stated priority group includes people with a BMI from 35 to 39.9 kg/m² and four or more of the specified weight-related conditions; higher-BMI groups began earlier. Local pathways, clinical assessment and service capacity still apply.

Someone who meets the broader NICE recommendation may therefore be eligible in principle but not yet fall within the current NHS priority cohort. A GP or local weight-management service can explain the pathway available in the patient’s integrated care board area.

NHS treatment in England is subject to the normal prescription-charge rules. Some patients pay the standard NHS prescription charge and others qualify for free prescriptions. Arrangements differ in Scotland, Wales and Northern Ireland, and local availability may not match the English rollout.

Who May Be Eligible for a Private Prescription?

The UK marketing authorisation permits tirzepatide for weight loss and weight maintenance, alongside a reduced-calorie diet and increased physical activity, in adults with:

a BMI of 30 kg/m² or above; or
a BMI from 27 kg/m² to below 30 kg/m² and at least one weight-related health condition.

This describes the population for which the medicine is licensed; it does not create an automatic right to a prescription. A prescriber must still decide that it is appropriate for the individual.

Assessment normally considers:

current BMI and weight history;
existing medical conditions;
current medicines, including insulin or sulphonylureas;
previous weight-management approaches;
pregnancy, breastfeeding and contraception;
gastrointestinal, gallbladder or pancreatic history;
eating-disorder history or other factors affecting safe treatment;
whether the patient can be monitored appropriately.

A responsible service may request photographs, video identification, GP records or permission to contact the patient’s usual doctor. These checks are a safeguard, not unnecessary bureaucracy.

How Mounjaro Treatment Usually Begins

Mounjaro is injected under the skin once a week. The approved adult schedule starts at 2.5 mg once weekly for four weeks, followed by 5 mg once weekly. If a higher dose is clinically appropriate, the prescriber may increase it in 2.5 mg steps, with at least four weeks at each dose, up to 15 mg once weekly.

The starting dose allows the body to adjust and is not a step to skip. Patients should not increase the dose early, split a pen into unapproved doses or change the schedule to reduce cost. Any change should be agreed with the prescriber.

The Patient Information Leaflet provides instructions on injection, storage, missed doses and disposal. A clinician or pharmacist should demonstrate correct use where necessary.

What Results Should Patients Expect?

Response varies. Clinical trials show that tirzepatide can produce substantial average weight loss when combined with lifestyle support, but trial averages do not predict an individual result. Dose, treatment duration, side effects, adherence, starting health and changes to eating and activity all influence the outcome.

NICE advises reviewing whether to continue if a person has lost less than 5% of their initial weight after six months on the highest tolerated dose. This is a clinical decision that should consider the individual benefits and risks.

Weight can return after treatment stops, particularly if appetite increases and sustainable habits or alternative support are not in place. Anyone thinking of stopping because of cost, side effects or pregnancy plans should discuss a safe plan with the prescriber rather than discontinuing or switching medicines independently.

Common and Serious Side Effects

The most frequently reported effects are gastrointestinal. They can include:

nausea;
diarrhoea;
vomiting;
constipation;
abdominal discomfort or pain;
indigestion and reduced appetite.

They are often more noticeable when treatment begins or the dose increases and may lessen with time, but persistent symptoms require professional advice. Vomiting and diarrhoea can lead to dehydration.

Serious reactions are less common. The NHS and patient leaflet advise urgent medical attention for symptoms that may indicate:

acute pancreatitis, such as severe, persistent abdominal pain that may spread to the back, with or without vomiting;
a severe allergic reaction, including swelling of the throat or tongue and difficulty breathing;
gallstones or gallbladder inflammation, which can cause severe abdominal pain;
low blood sugar, particularly when tirzepatide is taken with insulin or a sulphonylurea.

This is not a complete list. Read the current leaflet and tell the prescriber about all medicines and medical conditions. Suspected adverse reactions can also be reported through the MHRA Yellow Card scheme.

Pregnancy and Contraception

Mounjaro should not be used during pregnancy, while trying to become pregnant or while breastfeeding. Current MHRA guidance advises stopping tirzepatide at least one month before trying to conceive and discussing the plan with a healthcare professional.

Tirzepatide may reduce the effectiveness of oral contraceptive pills around the start of treatment and dose increases. The MHRA advises people using the pill to add a barrier method, such as condoms, for four weeks after starting Mounjaro and for four weeks after every dose increase, or to discuss switching to a suitable non-oral method.

Anyone who becomes pregnant or thinks they may be pregnant while using Mounjaro should contact a healthcare professional promptly.

How to Check Whether a Provider Is Legitimate

Mounjaro should come from a regulated UK prescriber and pharmacy. Before ordering:

Search for the pharmacy on the General Pharmaceutical Council (GPhC) register in Great Britain or the Pharmaceutical Society of Northern Ireland register.
Confirm the named prescriber is registered with the appropriate professional regulator, such as the GMC, GPhC or NMC.
Check that the website provides a real UK business address, complaints process and clinical contact route.
Expect a meaningful medical assessment and identity verification.
Avoid sellers offering Mounjaro without a prescription or through social-media messages.
Do not buy pens labelled for another market, previously used pens or products that cannot be traced through a legitimate supply chain.

Very low prices can be a warning sign. Counterfeit or improperly stored injections may contain the wrong dose, no active ingredient or harmful substances. Cold-chain handling and genuine packaging matter.

Price Should Not Be the Only Decision

Cost is important because treatment may continue for an extended period, but the cheapest first pen is not necessarily the lowest-cost or safest service over time. Consider:

the full price at the dose you are likely to use;
access to a clinician when side effects occur;
monitoring and review arrangements;
clarity about dietary and activity support;
continuity if stock or prices change;
privacy and handling of medical information;
whether the provider communicates with the patient’s GP when clinically appropriate.

Avoid any service that promises a fixed amount of weight loss, guarantees eligibility or encourages rapid dose escalation.

Frequently Asked Questions

Can Mounjaro replace diet and exercise?

No. Its weight-management licence and NICE recommendation both specify use alongside a reduced-calorie diet and increased physical activity. Lifestyle support also helps preserve nutrition, strength and longer-term habits while appetite changes.

Does everyone need to reach 15 mg?

No. Fifteen milligrams is the maximum approved weekly dose, not a target for every patient. Some people remain on a lower dose because it is effective or better tolerated. Dose decisions belong with the prescriber.

Is the private prescription price the same everywhere?

No. Pharmacies set their own retail prices and include different services. Compare the total renewal cost, not only an introductory discount.

If I meet the private BMI criteria, can I get it on the NHS?

Not necessarily. The licensed private-prescribing population is broader than the NICE NHS recommendation, and NHS England is applying additional priority criteria during its phased implementation.

How long does treatment last?

There is no single duration for everyone. Obesity is a long-term condition, and treatment should be reviewed according to effectiveness, tolerability, health goals and clinical advice. Cost planning should account for the possibility of continued treatment rather than assuming a short course.

Can I switch providers to obtain a lower price?

It may be possible, but the new provider should verify the prescription history, current dose and suitability. Do not misstate the dose or order overlapping supplies. Ask both providers how records and continuity of care will be handled.

What should I do if side effects are difficult to manage?

Contact the prescriber rather than changing the dose yourself. Seek urgent help for severe or persistent abdominal pain, signs of a severe allergic reaction or other serious symptoms. NHS 111 can advise when urgent assessment is needed; call 999 for a medical emergency.

Final Thoughts

For private patients in the UK, Mounjaro commonly costs from around £130 to £375 for four weeks, with the total depending heavily on dose and provider. NHS access exists but remains clinically restricted and is being expanded in stages.

The safest comparison therefore looks beyond the starter price. Check the provider’s registration, the full treatment cost, the quality of assessment, the plan for follow-up and what happens if side effects, pregnancy plans, supply problems or affordability concerns arise. Mounjaro can be an effective option for appropriately selected patients, but it remains a prescription treatment that requires realistic expectations and ongoing clinical oversight.

Sources and Further Reading

NICE, Tirzepatide for Managing Overweight and Obesity: Recommendations
NICE, Information About Tirzepatide, Including Licensed Indication and List Prices
NICE, Information for the Public: NHS Access and Phased Eligibility
NHS, Tirzepatide: Uses and Side Effects
MHRA, GLP-1 Medicines for Weight Loss and Diabetes: What You Need to Know
Electronic Medicines Compendium, Mounjaro KwikPen Patient Information Leaflet
General Pharmaceutical Council, Check if a Pharmacy Is Registered

This article is for general information and does not replace an individual medical assessment. Prices and access criteria can change. Mounjaro is a prescription-only medicine; use it only as directed by a qualified healthcare professional.